SCHEDULE 13G: Divisadero Street Capital Discloses 5.3% Stake in AngioDynamics, Inc.

Divisadero Street Capital Management, LP and its affiliates have reported a passive beneficial ownership of 5.3% in AngioDynamics, Inc.'s common stock.

Summary

• Divisadero Street Capital Management, LP, along with William Zolezzi, Divisadero Street Partners, L.P., Divisadero Street Partners GP, LLC, and Divisadero Street Capital, LLC, collectively reported beneficial ownership of 2,137,081 shares of AngioDynamics, Inc. common stock.
• This aggregate ownership represents 5.3% of AngioDynamics, Inc.'s outstanding common stock.
• The filing was made under Rule 13d-1(b), indicating that the reporting persons are institutional investors and are not seeking to change or influence control of the issuer.
• The reporting persons hold shared voting and shared dispositive power over all 2,137,081 shares.
• The event requiring this filing occurred on June 2, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, the acquisition of a significant stake by an institutional investor, particularly one stating passive intent, can be viewed favorably as it signals confidence in the company without immediate activist pressure.

Positives

• The disclosure of a significant stake by an institutional investor group, such as Divisadero Street Capital Management, LP, can be interpreted as a vote of confidence in AngioDynamics, Inc.'s long-term prospects and valuation.
• The passive nature of the investment, as indicated by the Rule 13d-1(b) filing, suggests that the investors are not pursuing activist intentions, which can provide stability for current management and strategic direction.

Risks

• While the filing states no intent to influence control, a significant ownership stake by an institutional investor could still lead to increased scrutiny or potential future engagement if the investor's views on company performance or strategy diverge from management's.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding AngioDynamics, Inc.'s future financial performance or strategic outlook.

Industry Context

AngioDynamics, Inc. operates in the medical technology industry, specializing in minimally invasive medical devices. The investment by Divisadero Street Capital Management, LP reflects continued institutional interest in companies within the healthcare and medical device sectors, which are often viewed for their defensive characteristics and long-term growth potential driven by demographic trends and technological advancements.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional holder may influence investor perception and potentially the stock price, signaling increased institutional interest.
• Management: The passive nature of the investment, as stated in the filing, suggests no immediate pressure for strategic or operational changes from this new shareholder group.

Key Dates

Keywords

AngioDynamics, Divisadero Street Capital Management, ANGN, SEC filing, Schedule 13G, beneficial ownership, institutional investment, medical technology, common stock, passive investment